BioNexus Gene Lab Corp
No SEC Form 4 filings for $BGLC in the last 30 days.
See all $BGLC insider activity →BioNexus Gene Lab (BGLC) secured a 10-year exclusive licence for CogniAI Healthcare in Malaysia, with two 5-year renewal options. The deal includes a 10% royalty and 560,000 shares issued to Ruanyun Edai Technology, valued at $3.5 million, plus 150,000 shares for 500,000 RYET shares. Closing is subject to approvals and milestones.
Ruanyun Edai Technology (RYET) and BioNexus Gene Lab (BGLC) signed an agreement for an exclusive license of RYET's Cogni AI platform in Malaysia's healthcare sector. RYET will receive a 10% royalty and 560,000 BGLC shares. The deal aligns with Malaysia's healthcare digitalization efforts, though neither company is part of government programs. The license term is up to 20 years, with BGLC leading local implementation. The transaction is subject to closing conditions and has not yet closed.
This article provides detailed financial information and performance data for BioNexus Gene Lab Corp (BGLC) traded on NASDAQ. It includes stock price charts, key financial stats, company overview, news, and technical analysis, highlighting its current market capitalization and recent stock movements. The company operates in distribution services and also develops liquid biopsy tests.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BGLC (BioNexus Gene Lab Corp). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent BGLC coverage spans financial news, corporate actions and technology.
The licence expands BioNexus' AI‑healthcare footprint in Southeast Asia and adds a royalty stream, which could modestly boost revenue.
Positive impact from acquiring AI technology and a strategic partner.
BioNexus Gene Lab Corp (BGLC) shows stable trading activity with recent modest upward movement. The company's operations in distribution services and liquid biopsy development position it within the growing biotech sector.
Shareholders' approval of key proposals indicates strong support for management and strategic initiatives, potentially leading to positive market perception.
The partnership to commercialize VitaGuard in Southeast Asia is expected to positively influence BioNexus Gene Lab's stock, given the increasing demand for liquid biopsy diagnostics.
AlphAI scores every news story that mentions BGLC with an AI model for sentiment and relevance, and aggregates insider trades from BioNexus Gene Lab Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioNexus Gene Lab (BGLC) secured a 10-year exclusive licence for CogniAI Healthcare in Malaysia, with two 5-year renewal options. The deal includes a 10% royalty and 560,000 shares issued to Ruanyun Edai Technology, valued at $3.5 million, plus 150,000 shares for 500,000 RYET shares. Closing is subject to approvals and milestones.
1 min readRuanyun Edai Technology (RYET) and BioNexus Gene Lab (BGLC) signed an agreement for an exclusive license of RYET's Cogni AI platform in Malaysia's healthcare sector. RYET will receive a 10% royalty and 560,000 BGLC shares. The deal aligns with Malaysia's healthcare digitalization efforts, though neither company is part of government programs. The license term is up to 20 years, with BGLC leading local implementation. The transaction is subject to closing conditions and has not yet closed.
2 min readThis article provides detailed financial information and performance data for BioNexus Gene Lab Corp (BGLC) traded on NASDAQ. It includes stock price charts, key financial stats, company overview, news, and technical analysis, highlighting its current market capitalization and recent stock movements. The company operates in distribution services and also develops liquid biopsy tests.
3 min readBioNexus Gene Lab Corp. (NASDAQ:BGLC) held its 2025 annual meeting on December 24, where shareholders approved four key proposals. These included the election of four director nominees, the adoption of the company’s 2025 Equity Incentive Plan, and the ratification of JP Centurion & Partners PLT as their independent public accounting firm. An adjournment proposal for soliciting additional proxies was also approved.
2 min readBioNexus Gene Lab Corp. announced definitive agreements with Fidelion Diagnostics and Tongshu Biotechnology to commercialize VitaGuard, a liquid biopsy platform for minimal residual disease (MRD) testing. The partnership grants BioNexus commercialization rights in ASEAN, focusing on Singapore and Malaysia, and involves share exchanges between the companies. This collaboration aims to enhance accessibility of MRD testing in Southeast Asia and explore AI and companion-diagnostic programs.
4 min readBioNexus Gene Lab Corp (BGLC) released its Q3 10-Q report, revealing a slight revenue decrease to $6.94 million but an improved gross profit of $1.09 million. The company experienced a widened net loss of $(1.95) million due to increased operating expenses. Strategic initiatives include expanding genomic screening with Fidelion Diagnostics' VitaGuard™ MRD platform and transitioning Chemrex Corporation Sdn. Bhd. into a CDMO focusing on biotechnology.
3 min readCollaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in Asia Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC's Biotech Footprint in Asia ...
3 min readU.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 0.1% on Wednesday. Following the market opening Wednesday, the Dow traded up 0.06% to 44,660.57 while the NASDAQ rose 0.19% to 21,138.92. The S&P 500 also rose, gaining, 0.10% to 6,377.27.
4 min readKUALA LUMPUR, Malaysia, July 30, 2025 ( GLOBE NEWSWIRE ) -- BioNexus Gene Lab Corp. ( "BGLC", Nasdaq: BGLC ) and Fidelion Diagnostics Pte Ltd, a Singaporean company ( "Fidelion" ) today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a ...
3 min readShares of Interactive Brokers Group, Inc. IBKR rose sharply in pre-market trading after the company posted better-than-expected second-quarter results after Thursday's closing bell. Interactive Brokers reported quarterly earnings of 51 cents per share, which beat the analyst consensus estimate of ...
3 min read
